Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03353675 · ClinicalTrials.gov registry record · Phase 2
A Study Evaluating the Efficacy and the Safety of First-line Chemotherapy Combined With the Therapeutic Vaccine Named TG4010 and Nivolumab in Patients With Advanced Non-squamous Non-Small Cell Lung Cancer (NSCLC)
A Phase 2 study, sponsored by Transgene.
- Completed
- Registry status
- Phase 2
- Development phase
- 44
- Enrollment target
NCT03353675 is a Phase 2 study that has completed, run by Transgene. The registered enrollment target is 44 participants.
The verdict
NCT03353675, a Phase 2 study, has completed, sponsored by Transgene.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 44 participants
- Enrollment target
Study Summary
This is a multicenter, single arm, open label phase II study in treatment-naïve for advanced stage of the disease and immunotherapy-naïve patients with advanced non-squamous NSCLC and with \< 50% of tumor cells expressing programmed death-ligand 1 (PD-L1) by immunohistochemical (IHC) staining.
Interventions
- DRUG Nivolumab
- DRUG Chemotherapy
- BIOLOGICAL TG4010
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 44 participants |
| Start Date | 2018-01-05 |
| Est. Completion | 2021-02-17 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03353675
The ClinicalTrials.gov registry entry for NCT03353675 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 44 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Transgene, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Nivolumab is the first listed.
NCT03353675 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03353675 about?
NCT03353675 is a clinical study titled "A Study Evaluating the Efficacy and the Safety of First-line Chemotherapy Combined With the Therapeutic Vaccine Named TG4010 and Nivolumab in Patients With Advanced Non-squamous Non-Small Cell Lung Cancer (NSCLC)". This is a multicenter, single arm, open label phase II study in treatment-naïve for advanced stage of the disease and immunotherapy-naïve patients with advanced non-squamous NSCLC and with \< 50% of tumor cells expressing programmed death-ligand 1 (PD-L1) by immunohistochemical (IHC) staining.
What is the current status of trial NCT03353675?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 44 participants. The study started on 2018-01-05. Estimated completion is 2021-02-17.
What interventions are being tested in trial NCT03353675?
The interventions under investigation include: Nivolumab (DRUG), Chemotherapy (DRUG), TG4010 (BIOLOGICAL).
Who is sponsoring clinical trial NCT03353675?
This trial is sponsored by Transgene, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.